Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Pathway Genomics' BreastTrue Panel

Premium

Pathway Genomics has launched its BreastTrue High Risk Panel, a next-generation sequencing-based assay with deletion/duplication analysis to detect mutations in seven high-risk cancer susceptibility genes — BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53. The test can analyze DNA from either blood or saliva. In addition, it has now added the option for customers that test negative using its BRCATrue and BRCATrue Ashkenazi Jewish panels to reflex to the BreastTrue panel.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.